novo nordisk glp-1 medications launches its Wegovy Pill weight-loss drug to the US market, GoodRx discounts it Article » PBD

However, Novo said it will continue to manage shipments of the drugs 0.25 mg starter dose to responsibly initiate patients on treatment. Novo is the maker of the wildly popular Ozempic and its weight loss counterpart Wegovy, both formulations of semaglutide

Once you understand your calorie range, the next challenge is finding meals that fit it without feeling heavy

Pancreatitis: GLP-1s can contribute to pancreatitis, or inflammation of the pancreas that can lead to complications if left untreated

Ozempic boosts insulin production and slows the rate at which food leaves the stomach, aiding in blood sugar stabilization